Brainomixa company that provides AI-driven imaging tools for stroke and pulmonary fibrosis, has announced the completion of its $18 million Series C investment round.
The round will be accompanied by existing investors Parkwalk Advisors. Boehringer Ingelheim Venture Fund.
New Investor hostplus and through the IP Group Hostplus Innovation Fund Lifesci Capital took part in the round.
What it does
Brainomix is an AI-powered software platform that enables precision medicine for better treatment decisions for stroke and pulmonary fibrosis. The company’s Brainomix 360 E-Lung technology predicts the progression of stroke and pulmonary fibrosis.
The company’s Brainomix 360 stroke automates imaging biomarkers aimed at enhancing diagnosis and treatment decisions.
The company will also partner with Boehringer Ingelheim to assess the actual effects of e-pulmonary and improve the identification and access to treatment for people with progressive pulmonary fibrosis.
Brainomix used its funds to accelerate its commercial expansion into the US and secured a 10 FDA clearance.
The funding supports BrainOmix’s strategy and advances its portfolio of AI-powered technology in new fields.
“We would like to thank all participating investors, including Parkwalk and the Boehringer Ingelheim Venture Fund, for their continued support and we welcome Hostplus, all of which recognize the transformational impacts they have on the treatment of patients with stroke and pulmonary fibrosis.
“We will leverage our European market leadership position and experience to help us achieve broader success in the US and improve patient care and access to life-changing treatments.”
Market Snapshot
In February, Brainomix partnered Medtronic neurovascular. The collaboration aims to enhance stroke care for patients in Western Europe by integrating AI solutions into clinical practice, expanding access to treatment and improving patient outcomes.
2023, Brainomix and Remote Robot Surgery Company NanoFlex Robotics We have announced the receipt of £400,000 ($420,418) and CHF 400,000 ($443,700) respectively to develop an AI-assisted magnetic navigation system for stroke-related robotic surgical tools.
In 2021, Brainomix closed a The Series B funding round has a total investment of approximately £16 million ($20 million). The Boehringer Ingelheim Venture Fund and the Oxford University Innovation Fund led the round with participation from Tencent Holdings.
